UBS analyst Ashwani Verma maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $15.00. The company’s shares closed yesterday at $12.10.
According to TipRanks, Verma is a 3-star analyst with an average return of 2.2% and a 47.62% success rate. Verma covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Cytokinetics, and Jazz Pharmaceuticals.
In addition to UBS, Teva Pharmaceutical also received a Buy from Barclays’s Balaji Prasad in a report issued yesterday. However, on January 25, J.P. Morgan assigned a Sell rating to Teva Pharmaceutical (NYSE: TEVA).
See today’s best-performing stocks on TipRanks >>
TEVA market cap is currently $13.55B and has a P/E ratio of -25.65.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical (TEVA) Company Description:
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
Read More on TEVA:
